Drug Information

Drug General Information
Drug ID
D08OLL
Former ID
DNC000349
Drug Name
BRL 44408
Drug Type
Small molecular drug
Indication Discovery agent Investigative [540718]
Structure
Download
2D MOL

3D MOL
Formula
C13H17N3
InChI
InChI=1S/C13H17N3/c1-10-12-5-3-2-4-11(12)8-16(10)9-13-14-6-7-15-13/h2-5,10H,6-9H2,1H3,(H,14,15)
InChIKey
SGOFAUSEYBZKDQ-UHFFFAOYSA-N
CAS Number
CAS 118343-19-4
PubChem Compound ID
121850
PubChem Substance ID
6319095, 7978818, 10239835, 14797826, 26752093, 29302354, 47434918, 47731316, 50064228, 57339809, 76715677, 79858254, 85208984, 103504481, 104414427, 129233046, 134339795, 135077952, 135650025, 136350490, 137007033, 162220571, 163122375, 164837131, 179293767, 184595743, 204378310, 233197573
Target and Pathway
Target(s) Alpha-2A adrenergic receptor Target Info Antagonist [534977], [535225]
KEGG Pathway cGMP-PKG signaling pathway
Neuroactive ligand-receptor interaction
PANTHER Pathway Alpha adrenergic receptor signaling pathway
Reactome Adrenoceptors
Adrenaline signalling through Alpha-2 adrenergic receptor
Adrenaline,noradrenaline inhibits insulin secretion
G alpha (i) signalling events
G alpha (z) signalling events
Surfactant metabolism
WikiPathways Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Platelet Aggregation (Plug Formation)
Integration of energy metabolism
GPCR ligand binding
GPCR downstream signaling
References
Ref 540718(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 525).
Ref 534977Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol. 2000 Apr;278(4):H1075-83.
Ref 535225Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.